Prothena Corp Public Ltd Co (PRTA) company profile
Close on Nov 13, 2026Market cap $418.91MP/E –Yield –
About Prothena Corp Public
Pharmaceutical Preparations, SIC 2834
Prothena Corporation plc is a clinical-stage biotechnology company that discovers and develops therapies for neurodegenerative conditions and rare peripheral amyloid diseases caused by protein dysregulation. Its research focuses on targeting pathogenic misfolded proteins while preserving normal biological function. The company's pipeline includes investigational antibody candidates such as prasinezumab for Parkinson’s disease, coramitug for ATTR amyloidosis, and BMS-986446 alongside PRX012 for Alzheimer’s disease, in addition to proprietary CYTOPE technology for intracellular disease targets. Prothena partners with global pharmaceutical corporations, including Roche, Novo Nordisk, and Bristol Myers Squibb, which advance clinical trials and commercialization to serve patient populations with limited treatment options.
The company is incorporated and registered as a public limited company in Ireland. Its operational reach spans international clinical and research programs, featuring multicenter clinical trials and worldwide licensing partnerships with multinational pharmaceutical enterprises across the United States and global territories.
Summary of the business section of Prothena Corp Public's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Prothena Corp Public Ltd Co
- Founded
- 2012
- Headquarters
- Dublin 2, L2
- Address
- 77 Sir John Rogerson'S Quay, Block C, Grand Canal Docklands D02 VK60
- Phone
- 011-353-1-236-2500
- Website
- prothena.com
- Employees
- 67, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L2
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Francisco, CA
Stock & identifiers
- Ticker
- PRTA
- Exchange
- Nasdaq
- IPO date
- Dec 21, 2012
- Shares outstanding
- 51M, Jul 30, 2026
- Public float
- $326.60M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1559053
- CUSIP
- G72800108
- FIGI
- BBG003PDKJF7
- Share class FIGI
- BBG00393H6N0
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gene G. Kinney | President and CEO, Director | 68,793 |
| Karin L. Walker | Chief Accounting Officer | 25,000 |
| Brandon S. Smith | Chief Operating Officer | 52,000 |
| Michael John Isaacs | General Counsel & Company Sec. | 35,745 |
| Chad J. Swanson | Chief Development Officer | 44,200 |
| Anne Evans Kingston | Chief Strategy Officer | 55,782 |
| Tran Nguyen | Chief Strategy Officer and CFO | 40,205 |
| Wagner M. Zago | Chief Scientific Officer | 85,000 |
| Michael J. Malecek | Chief Legal Officer | 80,000 |
| David A. Ford | Chief People Officer | – |
| Carol D. Karp | Chief Regulatory Officer | 5,000 |
| Shane Cooke | Director | 5,000 |
| Lars Ekman | Director | 3,148 |
| Richard T. Collier | Director | 6,219 |
| Dennis J. Selkoe | Director | 4,208 |
| Daniel G. Welch | Director | – |
| William H. Dunn Jr. | Director | – |
| Paula K. Cobb | Director | – |
| Helen Susan Kim | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $5.90M | $2.87M | $2.58M | $80 | $120 |
| FY2024 | $7.23M | -$1.71M | $2.49M | $115 | $91 |
| FY2023 | $7.04M | -$3.22M | $2.64M | $303 | $92 |
| FY2022 | $6.74M | $7.40M | $2.70M | $502 | $89 |
| FY2021 | $4.92M | $41.14M | $2.85M | $411 | $99 |
| FY2020 | $3.43M | $62.29K | $1.59M | $76 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Gene G. Kinney, Ph.D. President and Chief Executive Officer | $692.97K | $961.80K | $3.81M | $415.78K | $15.75K | $5.90M | -18% |
| Tran B. Nguyen Chief Strategy Officer and Chief Financial Officer | $600.39K | $652.65K | $1.09M | $300.20K | $15.75K | $2.66M | +3% |
| Brandon S. Smith Chief Operating Officer | $540.71K | $893.10K | $1.09M | $270.36K | $15.75K | $2.81M | +12% |
| Chad J. Swanson, Ph.D Chief Dev. Officer | $516.67K | $583.95K | $1.09M | $206.67K | $15.75K | $2.42M | – |
| Wagner M. Zago, Ph.D. Chief Scientific Officer | $514.22K | $583.95K | $1.09M | $205.69K | $15.75K | $2.41M | -0% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 67 employees, including 13 who held M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 22, 2020 | Name change | Name changed from Prothena Corp plc to Prothena Corp Public Ltd Co |
| Dec 21, 2012 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 21, 2012 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Oct 1, 2012 | Name change | Name changed from Neotope Corp Ltd to Prothena Corp plc |
| Oct 1, 2012 | Spin-off | Registration as a new public company (Form 10), e.g. spin-off |
See a number that looks wrong?